Cargando…
The changing treatment landscape in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significa...
Autor principal: | Costabel, Ulrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487773/ https://www.ncbi.nlm.nih.gov/pubmed/25726557 http://dx.doi.org/10.1183/09059180.00011414 |
Ejemplares similares
-
Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics Concluding remarks
por: Costabel, Ulrich
Publicado: (2013) -
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017) -
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
por: Bonella, Francesco, et al.
Publicado: (2023) -
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
por: Raghu, Ganesh
Publicado: (2017) -
Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
por: Costabel, Ulrich, et al.
Publicado: (2018)